- 期刊
The Beneficial Effects of Rho-kinase Inhibitor in Pulmonary Hypertension: From Bench to Bedside
並列摘要
Until recently the diagnosis of idiopathic pulmonary hypertension was synonymous with fatality. This was particularly true for children, in whom the mean survival was less than 1 year. Accordingly, pulmonary hypertension resulting from different causes include idiopathic pulmonary hypertension, left to right shunt congenital heart disease, collagen diseases, left heart dysfunction and HIV infection etc., are characterized by pulmonary arteriolar remodeling and an imbalance between vasoconstrictors and vasodilators, so-called endothelial dysfunction. Significantly improved progress in the therapeutic field of pulmonary hypertension has occurred over the past decades, and improves quality of life and survival in patients with PH, such as endothelin receptor antagonists, prostaglandin derivatives and eNOS-NO-cGMP axis related agents. Combination therapies are frequently needed to treat this fatal disorder, and new therapeutic agents are still being studied. Therefore, we try to discuss the future of therapeutic effects of Rho-kinase inhibitor on pulmonary hypertension. (J Pediatr Resp Dis 2012; 8:19-24)
延伸閱讀
- 戴任恭、吳俊仁、譚棉心（2004）。Advancing Pharmacological Therapy for Pulmonary Hypertension in Children。Acta Paediatrica Taiwanica，45(s)，1-5。https://doi.org/10.7097/APT.200411.0001
- Chen, Y. F., Li, H. B., Elton, T. S., Yang, R. H., Jin, H. K., & Oparil, S. Z. (1994). The Role of Atrial Natriuretic Peptide and Endothelin in Hypoxia Induced Pulmonary Hypertension. The Chinese Journal of Physiology, 37(3), 165-183. https://www.airitilibrary.com/Article/Detail?DocID=03044920-199409-37-3-165-183-a
- Ng, F. K. (2011). The influence of a protein kinase A inhibitor on interstitial adenosine of muscle at rest and during contraction [master's thesis, The University of Hong Kong]. Airiti Library. https://www.airitilibrary.com/Article/Detail?DocID=U0029-1812201200018800
- Chen, Y. J., Lin, Y. W., Chen, J. H., Lin, K. I., Lim, Y. Y., Tang, S. T., Yang, C. H., Pan, S. F., Chen, K. H., & Chen, M. J. (2012). Activation of the Peroxisome Proliferator-Activated Receptor Preventing he Monocrotaline-Induced Pulmonary Hypertension. Adaptive Medicine, 4(3), 155-164. https://doi.org/10.4247/AM.2012.ABC034
- Rameh, V., & Kossaify, A. (2016). Role of Biomarkers in the Diagnosis, Risk Assessment, and Management of Pulmonary Hypertension. Biomarker Insights, 2016(), 85-89. https://doi.org/10.4137/BMI.S38323